Ata Rai Decision

ATA RAI Remnant Ablation / Adjuvant Therapy Decision Tool

Source: 2015 ATA Management Guidelines — Recommendations 51–55 and Table 14.
Haugen et al. Thyroid 2016;26(1). DOI: 10.1089/thy.2015.0020

PREREQUISITE

Before making a RAI decision:

1. Assign the ATA Initial Risk Tier (Low / Intermediate / High) → use the ATA DTC Risk Stratification skill
2. Confirm surgery: near-total or total thyroidectomy (RAI decision is only relevant after total/near-total thyroidectomy)
3. Confirm no contraindications: pregnancy, lactation, iodine overload (recent CT contrast)

STEP 1 — Understand the Three Indications for RAI

STEP 2 — Apply the Risk-Stratified Decision Framework

❌ ATA LOW Risk — RAI NOT Routinely Recommended

Applies to:

• Unifocal PTC ≤1 cm (T1a) — intrathyroidal, no ETE, no LN involvement
• Intrathyroidal PTC T1b–T2 (1–4 cm), N0, no aggressive histology, no vascular invasion
• Intrathyroidal FTC with capsular invasion only or minimal vascular invasion (≤3 foci)
• Intrathyroidal multifocal PTMC (all foci <1 cm) without other risk factors

Rationale: RAI remnant ablation has not been shown to reduce recurrence or mortality in these patients. Surveillance with Tg and neck US is sufficient.

Exception — consider RAI even in Low Risk if:

• Aggressive histologic subtype (tall cell, hobnail, columnar)
• Vascular invasion present
• Patient/clinician preference for complete ablation to facilitate surveillance

🔄 ATA LOW–INTERMEDIATE Risk (T3 N0 or pN1a) — CONSIDER RAI

Applies to:

• Microscopic ETE (pT3a) into perithyroidal soft tissue, N0
• pN1a (central neck nodes positive) — ≤5 nodes, all <3 cm
• T1–T2 with 1–4 positive central nodes <0.2 cm (low-volume)

Decision: Individualise based on:

• Number and size of positive nodes
• Presence of vascular invasion
• Aggressive histologic features
• Patient age and comorbidities
• Post-surgical Tg level

→ If nodes are ≤5 micrometastases all <0.2 cm → may not require RAI
→ If >5 positive nodes or any node >0.2 cm but <3 cm → RAI generally favored

✅ ATA INTERMEDIATE Risk (pN1a or pN1b, aggressive features) — RAI GENERALLY RECOMMENDED

Applies to:

• Microscopic ETE with RAI-avid neck uptake on first scan
• Aggressive histologic subtype
• PTC with vascular invasion
• pN1 (central or lateral) with >5 nodes, all <3 cm
• Multifocal PTMC with ETE + BRAF mutation

Rationale: Adjuvant RAI reduces recurrence risk in this group; evidence supports benefit even without distant metastases.

✅✅ ATA HIGH Risk — RAI ROUTINELY RECOMMENDED

Applies to:

• Gross extrathyroidal extension (macroscopic pT4)
• Incomplete surgical resection (R1 or R2)
• Distant metastases (M1)
• Postoperative Tg suggesting distant disease
• pN1 with any single node ≥3 cm
• FTC with extensive vascular invasion (≥4 foci)

Rationale: RAI is a primary therapeutic agent. Dosing should be tailored to disease burden.

STEP 3 — RAI Administration Practicalities

Preparation

• Thyroid hormone withdrawal (preferred for high-risk and treatment doses): stop levothyroxine 3–4 weeks before; switch to T3 for 2 weeks, then stop T3 2 weeks before RAI
• Recombinant human TSH (rhTSH / Thyrogen): Acceptable alternative for remnant ablation (2 IM injections on Days 1 and 2; RAI on Day 3) — avoids hypothyroid morbidity; equivalent efficacy for ablation in low–intermediate risk
• Low-iodine diet: 1–2 weeks before RAI (restrict iodine intake to <50 mcg/day)
• Hold iodine-containing agents: Recent IV contrast → delay RAI 6–8 weeks; amiodarone → prolonged delay

Administered Activity

Note: 30 mCi has been shown equivalent to 100 mCi for remnant ablation in ESTIMABL and HiLo trials — use lower dose for remnant ablation in low-risk patients to minimise adverse effects.

STEP 4 — Post-RAI Assessment

• Post-treatment whole body scan (Rx-WBS): Perform 5–8 days after RAI administration
  • Identifies previously unknown metastatic foci
  • Positive neck uptake in the thyroid bed is expected; uptake elsewhere changes staging and management
• Serum Tg + anti-Tg antibodies: Measure at time of RAI preparation (TSH-stimulated)
  • Document baseline for future comparisons
• Follow-up: 6–12 months → thyroid neck US + TSH-stimulated or suppressed Tg → reclassify using dynamic risk stratification

CLINICAL GUARDRAILS

• Don't give RAI reflexively — ATA Low-risk unifocal T1a PTC has no proven benefit from RAI; avoid unnecessary treatment
• rhTSH vs. withdrawal is not equivalent for all patients — rhTSH is acceptable for remnant ablation in low–intermediate risk; for known distant disease, withdrawal may be preferred (higher TSH levels may improve RAI uptake)
• 30 mCi is enough for remnant ablation — do not dose-escalate to 100 mCi for pure remnant ablation in low–intermediate risk patients
• Iodine load is a contraindication — check for recent CT contrast before scheduling RAI; a 6–8 week delay is required after IV iodinated contrast
• Anti-Tg antibodies interfere with Tg assays — if anti-Tg is positive, Tg cannot be reliably interpreted; document and track anti-Tg trend instead
• Whole body scan for staging, not routine screening — do not perform diagnostic WBS routinely before RAI in low-risk patients; it adds radiation exposure without management benefit
• Breastfeeding must be stopped ≥6 weeks before RAI — and is contraindicated for 4–8 weeks after RAI
• Pregnancy is an absolute contraindication — confirm β-hCG negative before RAI in women of childbearing potential